PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Michael S. Broder, MD, MSHS, in collaboration with F. Hoffmann-La Roche/Genentech, Inc., compared mortality and hospitalization between Medicare beneficiaries with idiopathic pulmonary fibrosis (IPF) who initiated antifibrotic therapy and those who did not receive treatment. This retrospective observational study of Medicare beneficiaries using the 100% Medicare Research Identifiable Files showed that antifibrotic treatments reduce hospitalization and death among older patients with advanced age (>80 years), which is a population that has been excluded from key clinical trials despite being disproportionately affected by IPF. The study can be read in the December issue of the Journal of Managed Care + Specialty Pharmacy.